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Cell therapy improves cardiac function. Few cells have been investigated more
extensively or consistently shown to be more effective than c-kit sorted cells; however,
c-kit expression is easily lost during passage. Here, our primary goal was to develop an
improved method to isolate c-kitpos cells and maintain c-kit expression after passaging.
Cardiac mesenchymal cells (CMCs) from wild-type mice were selected by polystyrene
adherence properties. CMCs adhering within the first hours are referred to as rapidly
adherent (RA); CMCs adhering subsequently are dubbed slowly adherent (SA). Both
RA and SA CMCs were c-kit sorted. SA CMCs maintained significantly higher c-kit
expression than RA cells; SA CMCs also had higher expression endothelial markers. We
subsequently tested the relative efficacy of SA vs. RA CMCs in the setting of post-infarct
adoptive transfer. Two days after coronary occlusion, vehicle, RA CMCs, or SA CMCs
were delivered percutaneously with echocardiographic guidance. SA CMCs, but not RA
CMCs, significantly improved cardiac function compared to vehicle treatment. Although
the mechanism remains to be elucidated, the more pronounced endothelial phenotype of
the SA CMCs coupled with the finding of increased vascular density suggest a potential
pro-vasculogenic action. This new method of isolating CMCs better preserves c-kit
expression during passage. SA CMCs, but not RA CMCs, were effective in reducing
cardiac dysfunction. Although c-kit expression was maintained, it is unclear whether
maintenance of c-kit expression per sewas responsible for improved function, or whether
the differential adherence property itself confers a reparative phenotype independently of
c-kit.
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INTRODUCTION
Following myocardial infarction, the loss of contractile units causes left ventricular dysfunction
and is the major barrier to treating heart failure. The field of cardiac regeneration developed to
address this question and was predicated on the concept of administering a stem or progenitor
cell with sufficient potency to regenerate the damaged heart (Orlic et al., 2001). Thus, far, the
field has collectively failed to deliver on this promise; however, there is reason for optimism.
Although a master cardiomyocyte precursor has not been unequivocally identified, and most cell
therapy Studies provide little evidence of injected cells differentiating into cardiac myocytes, solid
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evidence supports the efficacy of cell therapy in preclinical
models (Bolli and Ghafghazi, 2015; Golpanian et al., 2016), and
the results of clinical trials have been encouraging, suggesting that
cell therapy is both safe and effective in patients with heart failure
(Khan et al., 2016). The task remains to identify what factors
affect the efficacy of cell therapy (Keith and Bolli, 2015).
Adoptive transfer of various types of progenitor/mesenchy
mal/stromal/stem cells attenuates cardiac dysfunction in
preclinical heart failure models (Keith and Bolli, 2015). Of
the various markers used to identify cells used in therapeutic
applications, c-kit sorted cells (Beltrami et al., 2003) are among
the most extensively studied cells in the field of regenerative
medicine. The receptor tyrosine kinase, c-kit, is a putative marker
of cardiac stem/progenitor cells, and although some studies have
shown that c-kit sorted cells transdifferentiate to cardiomyocytes
(Nadal-Ginard et al., 2014; Torella et al., 2014; Waring et al.,
2014), others have been unable to reproduce this finding (Keith
and Bolli, 2015). Nuanced controversies notwithstanding, it
is clear from multiple studies that c-kit sorted cells reliably
attenuate cardiac dysfunction. Whether maintenance of c-kit
expression is required for the beneficial effects of cell therapy
with c-kit sorted cells remains unanswered. In fact, few studies
involving c-kit sorted cells clearly report the maintenance of
c-kit expression after passage; our experience has been that
expression is lost (Zafir et al., 2013, 2015; Salabei et al., 2015). If
c-kit expression is necessary for the effectiveness of c-kit cells, we
should be intentional about identifying a reproducible approach
to stabilize c-kit expression during passage—this was a primary
goal of the present study.
Here, we refined an uncomplicated protocol to isolate c-kit+
cells with a goal of preserving c-kit expression in the majority
of cells through several passages. This involved modification
of initial cell plating after tissue digestion and improvement of
the sorting procedure, which allowed us to monitor cell purity
directly after sorting. We immunophenotyped the resulting cells
and used them along with parallel “control” cells to test whether
they were effective in attenuating infarct-induced heart failure.
An additional feature of our present study was the use of
echocardiographically guided percutaneous delivery to the left
ventricular lumen, which enabled intravascular delivery of the
cells. Thus, we were able to provide details for the isolation and
culture of cardiac mesenchymal cells (CMCs) with stable c-kit
expression, and characterize their effectiveness in the setting of
infarct-induced heart failure.
MATERIALS AND METHODS
C-Kitpos Cardiac Mesenchymal Cell
Isolation and Culture
All animal procedures were performed in compliance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and were approved by the University
of Louisville Institutional Animal Care and Use Committee.
Myocardial cells were isolated from 12 to 15 week old, male
C57BL6 mice (Jackson Laboratory). Mice were euthanized by
sodium pentobarbital injection (i.p. 100mg/kg) and cardiac
excision. The excised hearts were washed in room temperature
PBS, minced into small pieces and enzymatically dissociated
with Collagenase II (5µg/mL in PBS; Worthington) with gentle
agitation for 45min at 37◦C. After Collagenase II inactivation
with DMEM/F12 medium containing 10% FBS cells were
centrifuged at 600 × g for 10min. The collected cell pellet
was suspended in growth medium consisting of DMEM/F12
(Invitrogen), 10% FBS (Seradigm, VWR), bFGF (10 ng/ml), EGF
(10 ng/ml), LIF (10 ng/ml), ITS (insulin/transferrin/selenium),
glutamine and Pen-Strep. Two c-kitpos cell isolation methods
were used. They differed in initial seeding of the digested hearts
and cell labeling for c-kit sorting (direct vs. indirect method).
The indirect staining procedure allowed evaluation of the c-
kit sort purity directly after magnetic selection. In the standard
procedure (Supplementary Figure 1A) a single-cell suspension
was plated in the tissue culture flask. Twenty-four hours later,
floating cells were removed; attached cells were washed with
PBS and suspended in the growth medium. After cells reached
70% confluence (4–6 days of expansion), c-kitpos cells were
sorted using c-kit MicroBeads (Miltenyi Biotech) according to
the manufacturer’s recommendations. In the new procedure
(Supplementary Figure 1B), non-adherent cells were removed 2 h
after initial plating, and attached cells were gently washed with
PBS and suspended in the growth medium. Collected floating
cells were plated in new tissue culture flasks and cultured for
the next 2 h. The procedure was repeated three more times after
24, 48, and 72 h. A total of five fractions were collected from
the myocardial digestion. The cell fractions that attached within
2 and 4 h (fractions 1′ and 2′, respectively) were collectively
dubbed “rapidly adherent” (RA) and cells that attached in 24, 48,
and 72 h (fractions 3′, 4′, and 5′, respectively) were designated
“slowly adherent” (SA). After cells reached 70% confluence (4–
6 days of expansion), c-kitpos cells from individual myocardial
fractions were sorted with the MACS immunomagnetic labeling
method. Cells were detached by enzymatic digestion with 0.25%
trypsin-EDTA (Invitrogen), washed with PBS and stained with
rat monoclonal anti-mouse c-kit (clone 2B8) conjugated with
FITC (eBioscience) for 30min on ice. Subsequently, cells were
washed with PBS and stained with magnetic beads directed
against anti-FITC (Miltenyi Biotec) for 30min on ice. The
c-kit cells were sorted by positive selection using MS magnetic
columns. The sorted cells were analyzed for purity using flow
cytometry (LSRII, BD Biosciences). On average 85% purity was
obtained from all isolated fractions. Sorts with purity below 80%
were excluded from the experiments. One particular advantage
of the indirect staining procedure over the standard, direct
method is that the cell purity can be easily evaluated by flow
cytometry immediately after sorting without any additional cell
labeling.
Flow Cytometry
Myocardial cells were detached from culture dishes with 0.25%
trypsin-EDTA. After incubation for 30min at 4◦C with mAbs,
cells were washed then suspended in 0.5mL of PBS, and analyzed
via flow cytometry on an LSRII system. The following mAb were
used for characterization of cell phenotype were used (Table 1).
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TABLE 1 | Monoclonal antibody list.
Marker Fluorochrome Clone Company
CD90 PE 30-H12 eBioscience
CD29 PE HMb1-1 eBioscience
CD105 PE MJ7/18 eBioscience
CD73 PE TY/11.8 eBioscience
CD31 PE 390 eBioscience
c-kit APC Cy7 2B8 eBioscience
Sca1 Per CP Cy5 D7 eBioscience
CD45 APC Cy7 30-F11 BD Biosciences
Clonogenic Assay
Clonogenic potential was evaluated 7 days after sorting and
expansion. Using Terasaki plates, single cells were seeded in
10µL of growth medium per well. Single cell seeding was
confirmed on the day of seeding. The cells were grown for 14
days. Colonies of ≥30 cells were considered clonogenic; the
rate of clonogenicity was calculated as a percent of wells with
clonogenic cells per total number of seeded wells.
Real-Time PCR
Total mRNA was isolated with the RNeasy Mini Kit (Qiagen)
and reverse transcribed with TaqMan Reverse Transcription
Reagents (Applied Biosystems). Quantitative assessment of
mRNA markers of pluripotency (Pouf5f1, Nanog, Dppa1, Rif1),
cardiac (Nkx2-5, Gata4, Mef2c, Tbx5, Smarcd3, Tbx20, Myl4,
Myl7, Nppa, Nppb, Myh6, Myh7, Tnni3, Tnnt2, Gja5, Gja1,
Actin2), endothelial (Flt1, Cdh5, Vwf, Pecam1, Kdr), smooth
muscle (Myh11, Tagln, Smnt, Cnn1, Myocd, Srf), mesenchymal
(Thy-1, Ddr2, Col1a1, Col3a1) and β2-microglobulin was
performed by qRT-PCR using a StepOne (Applied Biosystems).
The primer sequences designed with the Primer Express software
have been previously described. A 25-µL-reaction mixture
containing 12.5µL of SYBR Green PCRMaster Mix and 10 ng of
forward and reverse primers was used. The threshold cycle (Ct),
i.e., the cycle number at which the amount of amplified gene of
interest reached a fixed threshold, was subsequently determined.
Relative quantitation of mRNA expression was performed with
the comparative Ct method. The relative quantitative value of
target, normalized to an endogenous control (β2-microglobulin
gene) and relative to a calibrator, was expressed as 2−11Ct (-
fold difference), where 1Ct = (Ct of target genes [Oct-4, Nanog
etc.]) − (Ct of endogenous control gene [β2-microglobulin]),
and 11Ct = (1Ct of samples for target gene) − (1Ct of
calibrator for the target gene). To avoid the possibility of
amplifying contaminating DNA (i) all of the primers for real-
time RT-PCR were designed to contain an intron sequence
for specific cDNA amplification; (ii) reactions were performed
with appropriate negative controls (template-free controls);
(iii) a uniform amplification of the products was rechecked
by analyzing the melting curves of the amplified products
(dissociation graphs); and (iv) the melting temperature (Tm)
was 57–60◦C, and the probe Tm was at least 10◦C higher
than primer Tm.
Murine Model of Myocardial Infarction
Adult (12–20 week) male mice were subjected to non-reperfused,
in vivo coronary artery ligation to induce heart failure, as
described previously (Jones et al., 2003a, 2005; Greer et al., 2006;
Watson et al., 2010; Brainard et al., 2013; Sansbury et al., 2014)
and in accordance with the University of Louisville Animal Care
and Use Committee. Mice were anesthetized using a combination
of ketamine hydrochloride (50mg/kg) and sodium pentobarbital
(50mg/kg), administered intraperitoneally. Mice were then
intubated with PE-60 tubing and mechanically ventilated, with
100% oxygen supplemented via the ventilator side port. Body
temperature was maintained at 37.0 ± 0.5◦C using a rectal
thermometer interfaced with a servo-controlled heat lamp. Using
sterile technique, mice were subjected to a thoracotomy and the
left coronary artery was visualized with the aid of a dissecting
microscope and permanently occluded with 7–0 silk suture.
After ligation, the chest and skin were closed using 4–0 silk
and polyester sutures, respectively. Mice were given 5mg/kg
ketoprofen, subcutaneously, for analgesia. Upon recovery of
spontaneous respiration, the intubation tube was removed and
mice were allowed to recover in a temperature-controlled area
supplemented with 100% oxygen. Mice were given additional
doses of ketoprofen (5mg/kg) by 24 and 48 h post-operatively.
Although some may lament the use of a non-reperfused model of
infarction, this is the most commonly used model for cell therapy
studies, which affords easier comparison between our study and
previous work.
Echocardiography
Transthoracic echocardiography of the left ventricle was
performed as previously described (Chang et al., 2001; Condorelli
et al., 2001; Jones et al., 2003a,b, 2004, 2005; Greer et al., 2006;
Watson et al., 2010, 2014; Wang et al., 2011, 2013; Brainard
et al., 2013; Muthusamy et al., 2014; Sansbury et al., 2014) with
a Vevo 770 echocardiography system. Body temperature was
maintained at 36.5–37.5◦C using a rectal thermometer interfaced
with a servo-controlled heat lamp. Mice were anesthetized with
2% isoflurane then maintained under anesthesia with ∼1.5%
isoflurane. Using the Vevo rail system, the mouse was placed
supine on an examination board interfaced with the Vevo
770. Next, depilatory cream was applied to the mouse’s chest
and wiped clean to remove fur from the chest. The 707-
B (30 MHz) scan head was used to obtain 2D images (100
fps) of the parasternal long axis; M-mode images were also
acquired from this position. The probe was then rotated 90◦
to acquire short axis views. Beginning at the base and moving
apically, serial 2D images were taken every millimeter. All
measurements were taken with the aid of the Vevo 770’s rail
system to maintain probe placement and allow for precise,
minute adjustments of probe position along the long axis. Left
ventricular diameters during diastole and systole (LVIDd and
LVIDs) were determined from long axis M-modes along with
heart rate (HR). Left ventricular fractional shortening (%FS)
was calculated as: ((LVIDd-LVIDs)/LVIDd) × 100%. Diastolic
and systolic volumes were determined by applying Simpson’s
rule of discs to the serially acquired short axis images. Stroke
volume (SV) was calculated as: diastolic volume - systolic
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volume. Ejection Fraction was calculated as: (SV/Diastolic
Volume)∗100%. Cardiac output was determined by: SV×HR.
Preparation of Cells for Injection
After cell sorting, RA and SA c-kitpos CMCs were expanded
for 3–5 passages. On the day of injection, cells were 60–80%
confluent. The cell monolayer was washed two times with room
temperature PBS to remove debris and dead cells. Subsequently,
cells were harvested by enzymatic digestion with 0.25% trypsin-
EDTA (Invitrogen). The resulting cell suspension was trypsin-
inactivated with DMEM/F12 supplemented with 10% FBS. After
centrifugation at 600× g for 10min at RT, cells were resuspended
in PBS and counted using a hemocytometer. Next, cells were
centrifuged for 10min at 600 × g and RT. A total of 106
cells were resuspended in 200µL of sterile PBS (pH 7.4) at
room temperature and transported to the echocardiography
laboratory for echo-guided percutaneous injection. The infusion
was performed within 10min after the last centrifugation of
the cells.
Echo-Guided Injection
At 48 h after MI, mice were anesthetized with isoflurane (1.5%),
and kept supine on an examination board interfaced with the
Vevo 770. Depilatory cream was applied to the mouse’s abdomen
and wiped clean to remove all hair. Next, each side of the
lower abdomen was taped down to the platform with surgical
tape to keep the injection area taught. Mice were treated with
analgesic (5mg/kg ketoprofen; subcutaneously). The echo probe
was placed suprasternally to capture 2D, long-axis views of the
heart. The field of view was adjusted to include the presence of
the ribs (to avoid them during insertion of the needle). A 1mL
syringe was loaded with a 250µL volume of 106 cells (SA or
RA) or PBS alone, and a 27 ga (13mm length) needle was placed
onto the syringe. The syringe was loaded onto an injectionmount
(VisualSonics) with the needle’s bevel facing up. Once the needle
was in the frame of the B-mode image, the angle and height of
needle were determined based on the needle-guide feature on
the Vevo 770. Essentially, a diagonal line was drawn creating
a visual, virtual path of the needle such that a clear intercostal
path into the ventricle was made. The angle and height of the
needle were adjusted through fine control adjustments of the
injection mount until it approximated the needle-guide. Once
positioned, the needle was advanced into the skin and through
the intercostal space. The needle was slightly withdrawn to ensure
successful passage between the ribs and a clear path to the
ventricle was visualized. Then the needle was advanced into the
ventricle. The volume of the syringe was injected (over∼2 s) into
the ventricular cavity and the needle was withdrawn. Successful
deployment of cells or PBS was identified by a visual surge of
radio-opaque signal inside the ventricle via 2D imaging or the by
the infiltration of blood into the syringe. Anesthesia was quickly
discontinued and the mice were cleaned. The mice were placed
under a heat lamp to maintain body temperature until recovery.
Histology
After final echocardiography, hearts were arrested in diastole
with saturated KCl and CdCl2 (100mmol/L). The heart was
excised, the aorta was then cannulated, and the heart perfused
with PBS followed by 10% buffered formalin at 75mmHg
while the LV was perfused through an apical cannula with
formalin at 8mmHg (to preserve overall spherical geometry).
Hearts were then cut into 2mm cross sectional slices and
processed for paraffin embedding. Slices were cut into 4µm
sections for histology and immunofluorescent staining. LV area,
risk area, LV cavity area, and infarct area were measured in
Masson’s trichrome stained sections as previously described
(Tang et al., 2010, 2016). LV dilation and wall thinning was
measured by determining the expansion index as previously
described (Tang et al., 2010, 2016). Expansion index was
calculated as (LV cavity area/total area) × (non-infarcted
region wall thickness/risk region wall thickness). The risk
area was defined as the transmural area between the furthest
outer lateral progressions of the scar, which was defined by
Masson’s trichrome staining. Viable myocardium in the risk
area was determined as the difference between risk and scar
areas. Images were acquired digitally and areas measured using
ImageJ (1.37v).
WGA and Isolectin Staining
Short-axis, mid-ventricular, paraffin-embedded cardiac sections
were heated at 70◦C for 30min, then washed in xylene
twice for 5min to deparaffinize the slides. The subsequent
rehydration process consisted of washing slides in serial dilutions
of ethanol (100, 96, 96, 90, and 80%) for 5min each. Slides
were then washed in dH2O for 3min. The antigen retrieval
process entailed microwaving (GE, 1.55 kW microwave) slides
in citrate retrieval buffer [2.4 g/L sodium citrate tribasic
dehydrate (Sigma, S4641), 0.35 g/L citric acid (Sigma, C0759),
pH 6.0] at 100% power to induce boiling for 2–3min and
then at 20% power for 7–8min. Slides were allowed to cool
at room temperature for 30min. Slides were then washed in
1× DPBS (Sigma, D5652-10L) 3 times for 5min each. Staining
for wheat germ agglutinin (WGA), Isolectin B4, and DAPI:
Precautions were taken to shield slides from light exposure
during the staining process. Slides were incubated with 1×
WGA (ThermoFisher, W32464) for 30min at room temperature
and were subsequently washed with 1× DPBS 3 times for
3min each. Slides were then incubated with 1:25 Isolectin B4
(Vector Labs, FL-1201) for 1 h at room temperature. Slides
were then washed 3 times for 3min each with 1× DPBS. In
the final wash step, 50µL of DAPI (1 mg/mL, ThermoFisher,
D3571) was added to the 1× DPBS. Slides were again washed
with 1× DPBS 3 times for 3min each. Next, to reduce
autofluorescence of the heart muscle, slides were incubated with
Sudan Black [1 mg/mL in 70% ethanol (Sigma, 199664)] for
30min. Slides were then washed 6 times for 3min each with
1× DPBS. Finally, slides were mounted, dried, stored at 4◦C
and protected from light until confocal imaging. Cardiomyocyte
hypertrophy and capillary density were visualized using a Nikon
TE-2000E microscope interfaced with a Nikon A1 confocal
system. Slides were imaged with a 60× objective and excited
in series with a 405 nm laser for DAPI, a 488 nm laser for
Isolectin B4, and a 561 nm laser for WGA. Emission was band-
pass filtered through 450/50, 525/50, and 595/50, respectively.
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Cardiomyocyte areas were determined in cardiomyocytes with
centrally located nuclei. All confocal analyses were blinded
and performed using Nikon Elements software [64-bit, version
3.22.00 (Build 710)].
Statistical Analyses
Results are shown as mean ± SD. The statistical analysis
(GraphPad 5.0d) was conducted using student’s t-test or by one-
way ANOVA followed by Newman-Keuls Multiple Comparison
Test, when appropriate. Differences were considered statistically
significant if p < 0.05.
RESULTS
C-Kit Expression Is Lost in Classically
Isolated C-kitpos Cardiac Mesenchymal
Stromal Cells during Expansion
Although many groups have studied the role of c-kit-sorted
cardiac cells for treatment of heart failure, data regarding the
maintenance of c-kit expression during expansion is rare. First,
we isolated CMCs from mouse hearts using standard isolation
procedure (described in details inMaterials andMethods section;
see Supplementary Figure 1A). Enzymatically dissociated cells
were seeded for 24 h and adherent cells were expanded to
reach 70% confluence and subsequently sorted with magnetic
beads directly conjugated to the primary antibody directed
against c-kit. To confirm successful sorting, enrichment of c-kit,
pluripotency, and cardiac markers was evaluated by qPCR. The
mRNA enrichment for c-kit in positively sorted cells was ∼20×
compared to unsorted cells, which confirms successful sorting.
Enrichment for pluripotency markers Pouf5f1,Nanog andDppa3
was >10-fold while Rif1 reached 3-fold; cardiac markers Nkx2-5
(19-fold), Gata4 (3-fold), Mybpc3 (17-fold), and Tnni3 (5-fold)
were also elevated (Figure 1A).
Positively sorted cells were plated at a density of 2500 cells
per cm2 and expanded. At∼75% confluence, cells were passaged
(P) and evaluated for c-kit and Sca-1 expression (up to 11
passages). CMCs were initially ∼70% c-kitpos, which gradually
declined with further passaging (Figure 1B). In contrast, Sca-1pos
remained∼80% through P11 (Figure 1C).
Next, c-kit expression, pluripotency, and cardiac markers
were evaluated by qPCR in cells from P1 and P5. There was
a significant decline in c-kit, pluripotency markers (Pouf5f1,
Nanog, Dppa1, Rif1), and cardiac markers (Nkx2-5, Mybpc3,
and Tnni3) at P5 compared to P1; however, Gata4 expression
was not different (Figure 1D). Expression of mesenchymal and
profibrotic markers Cxcl12, Col1a1, Col3a1, Lox, Lolx3, Tgfb2,
and Tgfb3 was elevated (Figure 1E) at P5 compared to P1.
C-Kit, Pluripotency, and Cardiac Marker
Expression Is Higher in SA Compared to
RA CMCs
The standard isolation protocol is based on the principle
that c-kitpos CMCs possess adherent properties; however, no
systematic study has determined the time necessary for c-kitpos
CMCs to adhere to plastic. Here, we performed sequential plating
of freshly digested mouse hearts (described in Materials and
Methods; Supplementary Figure 1B). Five fractions were isolated
and designated as 1′, 2′, 3′, 4′, and 5′; these fractions adhered
to the culture plates within 2, 4, 24, 48, and 72 h, respectively.
The first two fractions, which adhere within hours, are called
RA; the remainder, which adhere within days, are dubbed SA
(Figure 2A). Quantitative PCR data show that SA CMCs have
∼9-fold higher mRNA expression of c-kit compared to RA
CMCs (Figure 2B) (Supplementary Figure 2A). Flow cytometric
analysis revealed that 2.5% of RA CMCs express c-kit (1′–2% and
2′–3%), while it is 6% in SA CMCs (3′–5%, 4′–8%, 5′–7%, 6′–3%;
Figure 2C) (Supplementary Figure 2B).
Next, the expression of pluripotency and cardiac markers
was evaluated by qPCR in the RA and SA cells. Similar to c-
kit expression, SA cells expressed higher levels of pluripotency
markers, Nanog, Dppa1, and Rif1, except Pouf5f1, which was
elevated but did not reach statistical significance. Cardiac
markers, Nkx2-5, Gata4, Mybpc3, and Tnni3, were also elevated
(Figure 2D). Collectively, these data suggest that c-kitpos CMCs
enriched for pluripotency and cardiac markers require days to
adhere to plastic. In principle, this strategy can be used to pre-
select cells c-kitpos CMCs for further enrichment using specific
surface markers.
Stabilized C-Kit Expression in SA CMCs
Promptly Declines in RA CMCs during
Expansion
Because the standard method of c-kit cell sorting does not
allow for monitoring of cell purity and sorting efficiency directly
after sort, we modified the c-kit cell sorting procedure. The
typical one-step method with primary antibody conjugated with
magnetic beads was replaced with a two-step method. The
primary antibody directed against c-kit conjugated with FITC
and secondary anti-FITC antibody conjugated with magnetic
beads. This allowed for a small sample of sorted cells to be
evaluated for purity by flow cytometry and the remaining
cells were expanded for further experiments (Supplementary
Figure 1B).
Next, we isolated RA and SA CMCs and expanded them. Once
they reached 70% confluence, c-kitpos cells were sorted with the
aforementioned, improved two-step method. The average purity
of sorted cells was 88% for both RA and SA CMCs (Figure 3A).
Sorted c-kitpos RA and SA CMCs were plated at a density of 2500
cells per cm2 and expanded. At 70% confluence, the cells were
passaged and evaluated for c-kit expression by flow cytometry.
The c-kitpos RA CMCs precipitously lost c-kit expression by
P4, and c-kit expression was maintained at vanishingly low
levels when the RA cells were continuously grown. Conversely,
c-kitpos SA CMCs maintained relatively high c-kit expression
through P6 (Figure 3A). These data indicate that SA CMCs have
more stable c-kit expression compared to RA CMCs; however,
continued passage of SA CMCs resulted in a further decline
of c-kit expression (data not shown). The comparison of c-kit
expression in RA and SA cells was performed at the same passage
after sorting and the c-kit sorted RA and SA CMCs cells were
plated at the dame density. Thus, it is unlikely that RA CMCs lose
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FIGURE 1 | Isolation and characterization of mouse c-kitpos CMCs. Enzymatically dissociated mouse hearts were left in culture medium for 24 h. When
reached 70% confluence (4–6 days of expansion), c-kit positive CMCs were positively selected using magnetic beads. (A) Immediately after sorting, qPCR was
performed to compare gene expression for c-kit, pluripotency markers, cardiac markers, and chemokine receptors (n = 5). C-kit (B) and Sca-1 (C) were monitored by
flow cytometry up to 11 passages after sort (n = 13). Gene expression comparison in c-kitpos CMCs between passage 1 and 5 (n = 4) (D,E). Values are mean ± SD
*p < 0.05 vs. vehicle.
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FIGURE 2 | Expression of c-kit, pluripotency and cardiac markers in CMCs isolated from RA and SA fractions. Schematics of CMCs RA and SA isolation
(A) expression of c-kit in CMCs from RA and SA fractions 4–6 days after isolation and expansion at mRNA level by qPCR (n = 4) (B) and protein level by flow
cytometry (n = 4) (C). Real-time PCR on cells from RA and SA cells without sorting (n = 3) (D). Values are mean ± SD *p < 0.05 vs. SA.
c-kit expression faster because they are attached earlier than SA
CMCs. Rather, this indicates there are fundamental population
differences between RA and SA cells related to the number of
cells expressing c-kit. Within the c-kit positive populations of
RA and SA cells, there was no difference in the intensity of
immunofluorescence associated with c-kit expression.
SA C-Kitpos CMCs Possess more Primitive,
Pro-Angiogenic, and Pro-Cardiogenic
Profile Cells
Clonogenicity is a hallmark of stem/progenitor cells, and because
c-kit has been touted as a cardiac stem cell marker, we queried
potential clonogenic differences between SA c-kitpos and RA
c-kitpos CMCs. The maintenance of c-kit expression in the
SA c-kitpos CMCs led us to speculate that they are more
primitive than RA c-kitpos CMCs. SA and RA c-kitpos CMCs were
expanded one passage after sorting and Terasaki plates were used
to test their clonogenicity. Individual cells were seeded per well,
which was verified via microscopy. Single cells were incubated for
14 days and evaluated for clonogenicity; wells with 30 or more
cells were considered to be clonogenic. The 1′ cells had lowest
clonogenicity of 0.6%, which increased to 1.9% in 2′, 5.0% in 3′,
6.6% in 4′ and 6.1% in 5′. Overall, the clonogenicity of RA c-kitpos
CMCs was lower than SA c-kitpos CMCs (Figure 3B). Despite
differences in clonogenicity, population-doubling times were not
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FIGURE 3 | Characterization of RA and SA c-kitpos CMCs. Flow cytometric analysis of c-kit expression in RA and SA c-kitpos CMCs (n = 3) (A). Clonogenicity
performed using Terasaki plates (n = 4) (B). Population doubling times (n = 7) (C). Expression of pluripotency markers by qPCR at mRNA level (n = 3) (D).
Mesenchymal and endothelial marker analysis by flow cytometry (n = 2) (E,F). Expression of endothelial (G), cardiac (H), smooth muscle (I) and mesenchymal (J)
markers evaluated by qPCR (n = 3). Values are mean ± SD *p < 0.05 vs. RA.
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different between the two c-kitpos CMCs lines (31.2 h in RA and
30.5 h in SA; Figure 3C).
Cell primitiveness is correlated with pluripotency marker
expression. SA c-kitpos CMCs mRNA levels of Pouf5f1, Nanog,
Dppa1, Rif1 were significantly higher than in RA c-kitpos
CMCs (Figure 3D). We also evaluated expression of classical
mesenchymal markers (and CD31) by flow cytometry. RA
c-kitpos CMCs were largely positive for mesenchymal markers
(i.e., CD90.2, CD105, CD29, CD73) (Supplementary Figure 3);
SA c-kitpos CMCs had a similar pattern of mesenchymal marker
expression, with the conspicuous exception of lower CD90.2
positivity. Interestingly, CD31 (endothelial marker) expression
was higher in the SA c-kitpos CMCs compared with RA c-
kitpos CMCs (Figures 3E,F). Using qPCR, we further evaluated
expression of endothelial markers (Flt1, Cdh5, Vwf, Kdr), which
were also significantly higher in SA c-kitpos CMCs compared
with RA c-kitpos CMCs. In addition, some cardiac markers
(Nkx2-5, Mef2c, Myl7, Nppa, Nppb, Myh6, Myh7, and Gja5)
were significantly higher in SA compared to RA c-kitpos CMCs
(Figures 3G,H). Expression of putatively profibrotic markers,
Col1a1 and Col3a1, were somewhat reduced, with Ddr2 reaching
statistical significance (Figures 3I,J).
Percutaneous Delivery of CMCs
After the cell populations were carefully characterized in vitro, we
established whether they could provide significant improvement
in cardiac function. There are several important elements to
the in vivo component of this study. First, the sonographers
and surgeons were blinded to the cells’ origin. Second, we used
both a standard vehicle control (these mice were subjected
to percutaneous ventricular luminal delivery of saline) and
another group receiving RA CMCs (i.e., a “cell control”). In our
estimation, the use of RA cells provided the most relevant control
possible—that is, cells that had been previously c-kit sorted and
were derived from the heart. Third, we used a non-reperfused
model of acute heart failure. This model was chosen for the
consistently large infarcts and robust depression of ventricular
function. Fourth, the percutaneous delivery of cells was chosen
for multiple reasons: (i) it is less invasive than open-chest
injections, which could limit experimental confounders; (ii) the
mice are likelier to survive; (iii) the cells access the myocardium
via the coronary circulation, which more closely resembles the
clinical route of delivery.
During our pilot studies to establish the percutaneous
delivery protocol, we spent significant time optimizing the
positioning of the probe (more suprasternal position than
typical PLAX echocardiograms in mice), in coordination with
the needle’s angle of attack. The surgeons and sonographers
worked together to establish the approach of the needle into the
visual field of the echocardiography probe, while negotiating
an intercostal access point. For those attempting this in their
own laboratories, the use of echo-opaque contrast agent should
help in confirming the locus of injection; however, the injection
of the cells provided sufficient monographic disturbance to
confirm their administration within the left ventricular lumen.
Although we injected cells into the left ventricular lumen,
this technique can also be employed for intramyocardial (i.e.,
directly into the muscle) injections; we confirmed the feasibility
of the intramyocardial approach during our pilot studies to
establish this technique. Although the focus of the percutaneous
delivery of cells naturally centers on the specific aspect of manual
administration of the cells, the success of this technique is
undoubtedly predicated on the quality of cells being prepared for
injection. As one last cautionary note, it was critical to position
the warming lamps so that the cells were not exposed to excessive
heat.
SA C-Kitpos CMCs, but Not RA C-Kitpos
CMCs, Preserve Myocardial Function
after MI and Reduce Fibrosis
Two days after MI, mice were subjected to an echocardiogram
to confirm sufficient depression of cardiac function (LVEF
< 50%). All mice included in the study had significantly
depressed cardiac function, and there were no differences
among the groups at treatment (2 days post-MI). At 37
days post-MI (35 days following cell/vehicle injection), mice
were subjected to their final echocardiograms. Mice treated
with RA cells did not significantly improve cardiac function
compared with vehicle treated mice; however, SA cell treated
mice exhibited significantly higher ejection fractions (Figure 4).
Additional echocardiography derived endpoints are presented
in the Supplementary Table 2. Moreover, Masson’s trichrome
staining showed that SA cell treated hearts, as compared to
vehicle, had increased infarct wall thickness, reduced scar area
and expansion index, while RA cells were ineffective (Figure 5).
SA C-Kitpos CMCs, but Not RA C-Kitpos
CMCs, Increase Vascular Density Post-MI
To address the issue of how the cells might improve cardiac
function, we examined potential changes in vascular density.
Using isolectin B4 staining, capillaries were counted in mid-
ventricular cardiac sections at 37 days post-MI (35 days following
cell/vehicle injection). Following infarction, there was a clear
reduction in capillary density in the ischemic and border zones
compared to the remote zone. In the ischemic zone, SA CMC
treatment significantly augmented capillary density compared to
vehicle treatment (Figure 6), and this trend was also reflected
in the border zone. In the remote zone, the capillary densities
were virtually indistinguishable among the three treatment
groups.
We also assessed cardiomyocyte cross-sectional area in the
same sections as the capillary counts. In the ischemic zone,
myocyte cross-sectional areas were relatively preserved in the SA
CMC (292 ± 46µm2), but not the RA CMC (213 ± 35µm2) or
the vehicle (181 ± 21µm2). In the border zone, cross-sectional
areas were similar among the vehicle (365 ± 33µm2), RA
CMC (280 ± 40µm2), and SA CMC (290 ± 36µm2). In the
remote zone, the myocyte cross-sectional areas were virtually
indistinguishable among the vehicle (299 ± 34µm2), RA CMC
(303 ± 32µm2), and SA CMC (281 ± 12µm2). Thus, most of
the pathologically identifiable changes associated with SA CMC
treatment occurred in the ischemic and border, but not remote,
zones.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 9 August 2016 | Volume 4 | Article 78
Wysoczynski et al. C-Kit Stabilization in CMCs
FIGURE 4 | Cardiac function 37 days after MI. Two days following myocardial infarction, vehicle, RA c-kitpos CMCs, or SA c-kitpos cMSCs, were percutaneously
injected with echocardiographic guidance into the lumen of the left ventricular cavity (A). Echocardiography was used to determine diastolic and systolic volumes; the
resulting ejection fractions are shown in (B). Representative frames from B-mode imaging (labeled PSLAX) and M-mode imaging are shown for the three groups in (C).
Values are mean ± SD. *p < 0.05 vs. vehicle.
DISCUSSION
The primary goal of this study was to establish a reproducible
protocol to maintain c-kit expression during passage of CMCs,
and to confirm whether the resulting cells had reparative
potential. We found that differential plating enriched c-kit
positivity of CMCs. This observation in the so-called SA CMCs
led us to query whether these cells represented a more refined
population of CMCs that are likelier to maintain c-kit expression.
To address this possibility, we modified an immunologic sorting
technique and passaged the resulting cells in conjunction with
the differential plating protocol described in the Materials and
Methods. The resulting (c-kit sorted) SA cells reproducibly
retained high levels of c-kit expression. These findings, alone, are
important for other investigators in the field.
After identifying a valid approach to stabilize c-kit expression,
we characterized the cells and identified a number of
immunophenotypic features of the SA CMCs, which are
putatively favorable for use in adoptive transfer studies. There
were several aspects of the in vivo study that are important to
highlight. First, the use of echo-guided percutaneous delivery
is still in the developmental stage, as reflected by a limited
number of publications using this technique in mice. In this
regard, we provide sufficient methodological detail (and online
video files) for other laboratories to adopt this technique. The
obvious primary advantage of the percutaneous approach is
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FIGURE 5 | Morphometric analysis. Representative Masson’s trichrome stained heart short axis sections from mice 35 days after injection of vehicle, RA, or SA
c-kitpos CMCs (A). Non-infarcted (i.e., Remote) and infarct wall thickness (B), scar as percent of LV (C) and expansion index (D). Values are mean ± SD. *p < 0.05
vs. vehicle.
FIGURE 6 | Pro-angiogenic activity of RA and SA c-kitpos CMCs in vivo. Capillary density in the ischemic zone (A) and border zone (B) of hearts 37 days after
MI was evaluated by isolectin B4 staining. Values are mean ± SD. *p < 0.05 vs vehicle (Veh).
the avoidance of a second thoracotomy in mice with heart
failure. Second, we administered the cells into the lumen of the
left ventricle, which creates a murine proxy for intracoronary
delivery. Intravascular delivery more closely approximates
most of the clinical trials using cell therapy. Because our cells
were administered into the lumen of the left ventricle, the
injected cell load was much higher than previous studies. We did
verify that this cell number and injection route led to a similar
level of engraftment as has been reported when others have
used an open-chest approach with fewer cells. Such technical
contributions should be quite useful to other investigators, and
certainly these techniques could be applied (and/or modified)
for any cell type.
Because this study focused on c-kit sorted cells (though
potentially a different cell population), we must acknowledge
some of the disagreement in the field. There seems to be a
popular notion that some studies (e.g., van Berlo et al., 2014)
have single-handedly invalidated dozens of others; however,
coherent evaluation of the literature supports a different view.
Specifically, the study by von Berlo and associates (van Berlo
et al., 2014) addressed the role of endogenous c-kit cells and
whether they become cardiomyocytes; their study did not address
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directly any issue related to adoptive transfer (i.e., cell therapy).
Their study did provide strong evidence that endogenous c-kit
cells contributed to endothelial cells, but not cardiomyocytes;
however, contrary to van Berlo et al. (2014), others maintain
that endogenous c-kit cells could contribute significantly to
cardiomyocytes (Torella et al., 2014). The role of endogenous
c-kit cells was not the focus of our present study, and we have not
studied the contribution of endogenous c-kit cells to myocardial
repair; our interests lie primarily in CMCs in the context of
cell therapy per se. Nevertheless, understanding the mechanisms
of endogenous repair is certainly valuable and hopefully future
studies may reconcile this interesting question.
Because we had not previously observed significant
transdifferentiation of our injected cells (Keith and Bolli,
2015), and many investigators have reported the production
of new blood vessels following cell therapy, we queried
whether SA CMCs imparted a pro-vascular phenotype.
Immunophenotypic characterization of c-kit-sorted SA CMCs
in vitro indicated an enrichment of cardiovascular lineage
markers. Most conspicuously, we observed endothelial/endothel
ial-like expression patterns in the c-kit-sorted SA CMCs, which
provided a natural, mechanistic segue to investigate. That is,
might the endothelial-like phenotype of our CMCs be relevant to
changes in the myocardium? Specifically, we evaluated whether
SA cells (with their pro-endothelial-like phenotype) might affect
neovascularization in the failing hearts. Indeed, inspection of the
hearts indicated an increase in capillary formation. Although
establishing a definite causal relationship was not the goal of
the present study, such insights provided potential avenues
to investigate in a more focused manner in future studies.
Nevertheless, others have also observed enhanced endothelial
cell proliferation and/or vascularization following cell therapy
(Khan et al., 2015; Quijada et al., 2015; Tang et al., 2016) and
perfusion improvements are evident in clinical trials (Khan
et al., 2016), which supports the notion that such an effect could
represent one of the ways cell therapy improves ventricular
function.
Collectively, cell therapy studies have used a menagerie
of cells. Yet, most of these cells do not convincingly
transdifferentiate into significant numbers of cardiomyocytes,
though they do improve cardiac function (Keith and Bolli,
2015). This suggests that many of the cells used thus far
provide a supportive or otherwise indirect reparative role. We
speculate that many of the cells used by investigators actually
represent related, though slightly different, populations of
what may be more appropriately classified as CMCs. This
could include cells of various levels of purported pluripotency,
as well as cells more traditionally considered as fibroblasts.
We have considered this, and related ideas, and posit
the following speculation. Perhaps the cells being used in
many cell therapy studies represent various subpopulations
(however heterogeneous they may be). Furthermore, these
cells may in fact contain subpopulations of cells that could
be viewed from traditional points of view as activated
fibroblasts, and these activated fibroblasts may participate
in myocardial repair.
The lack of a beneficial effect of RA CMCs is interesting for
several reasons. These data indicate that there are populations
of c-kit-sorted cells that give rise to non-reparative cells,
which is an innovative concept (i.e., c-kit sorting per se is
insufficient to guarantee reparative cells). It is, however, possible
that the c-kit sorted RA CMCs could have been outgrown
in culture by initially rare populations of c-kit negative (and
non-reparative) CMCs. In addition, our present data indicate
that more of the RA cells than SA cells are CD90.2 positive,
which indicates additional phenotypic differences beyond simply
losing c-kit expression. Again, whether this is due to shifts
in predominant subpopulations is possible but remains to
be elucidated. Moreover, studies of cells ex vivo are subject
to varying levels of artificiality. Indeed, some cell therapy
investigators are convinced that it is precisely the artificial
culturing of cells that elicits a salutary phenotype; the SA CMCs
may be no exception. It is also important to note that after
the initial selection process, SA cells are no longer appreciably
limited in their capacity to adhere. Again, like most cells,
SA cells likely undergo changes during ex vivo cell culture
conditions.We have not determined whether there is a significant
fraction of SA cells that do not adhere quickly following
passaging. This will be investigated intentionally in future
studies.
We predict that c-kit sorted cells may contain cells that
participate beneficially, neutrally, or antagonistically to cardiac
repair, and the differential plating step we described here
significantly enriches for the reparative population(s) of c-kit
sorted cells. Indeed, the present data indicate that cells isolated
based on c-kit positivity are not necessarily reparative (i.e.,
c-kit sorted RA cells); perhaps the reparative fraction of c-
kit cells is all (or largely) represented in the SA population.
It is conceivable that such technical differences may explain
apparent discrepancies in previous studies of adoptive transfer
of c-kit-sorted cells. One of the motivations for performing
this study was that the expression of c-kit was required
for the reparative effects of SA CMCs. Although this was
not tested specifically, if we assume a different view of the
conclusions, we may argue that the RA/SA segregation was
more important than c-kit sorting. In other words, sorting
for c-kit may have been irrelevant for the reparative effects
we report here; this is the subject of current efforts in the
laboratory.
In its simplest form, the present study establishes a refined
technique to enrich for reparative c-kit sorted cells (i.e., SA cells),
and employs them in a refined, minimally invasive model of
syngeneic adoptive transfer. Yet, in a broader context, this study
poses new questions regarding the absolute requirement based
on sorting for cell markers. We predict that the segregation
of cells based on their adherent phenotype, which may be a
proxy for reparative vs. non-reparative cells, may be a new and
singularly sufficient approach to cardiac cells with the potential to
repair the failing heart. Even if such speculation is not ultimately
validated, the combination of c-kit sorting with differential
plating yields a population of cells with clear reparative
capacity.
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